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The effect of an Ayurvedic poly-herbo-mineral formulation Kumarabharana Rasa (KR) in the management
of chronic tonsillitis (Tundikeri) in children has been assessed in this study. This clinical study was a
double-arm study with a pre- and post-test design at the outpatient level in a tertiary Ayurveda hospital
attached to a teaching institute located in district headquarters in Southern India. Patients (n ¼ 40) with
chronic tonsillitis satisfying diagnostic criteria and aged between 5 and 10 years were selected from the
outpatient Department of Kaumarbhritya, SDM College of Ayurveda and Hospital, Hassan. Among them,
20 patients were treated with Kumarabharana rasa (tablet form) at a dose of 500 mg once daily for 30
days (Group A). The other 20 patients were treated with Godhuma Vati (placebo) at a dose of 500 mg once
daily for 30 days (Group B). In both groups,Madhu was the Anupana advised. After completion of 30 days
of treatment, the patients were assessed on the following day and another investigation took place 15
days later. Statistically signiﬁcant effects (p < 0.05) in the reduction of all signs and symptoms of chronic
tonsillitis after KR treatment were observed. These results indicate that Kumarabharana Rasa has an
ameliorative effect in reducing the signs and symptoms of chronic tonsillitis.
Copyright © 2014, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. All rights reserved.1. Introduction
Chronic tonsillitis (CHT) is one of the most common otolar-
yngologic diseases.1 CHT is rare in infants and older people. In
young children, tonsillitis is one of the recurrent upper respiratory
tract infections. CHT is a highly prevalent disease in the pediatric
age group, and it peaks between 3 and 10 years of age and then
declines.2,3 In general practice children frequently visit with
recurrent throat problems4 and the incidence of this disease ac-
counts for about 7% of all visits to the pediatrician.3 Children with
CHT experience discomfort, and the disease also impacts on social,nd Hospital, Hassan 573 201,
nath).
for Food and Biomolecules,
molecules, National Taiwan Univeemotional, and ﬁnancial aspects for family members.5 Tonsilitis is
an infection of the tonsils.6e8 Despite its high prevalence, the eti-
ology of CHT has remained indistinct. The surface and deep bac-
terial ﬂora of chronic inﬂamed tonsils consist of an abundance of
probable pathogenic aerobic and anaerobic bacteria, primarily of
streptococcal origin.9e13 Tonsils are part of the immune system.
Therefore, due to the decrease in immunity and the tonsils'
incompetence in helping the immune system, they actually become
a source of recurrent infections.3 The current treatment option for
CHT is tonsillectomy, but it is not the ultimate solution. The
generally accepted criteria for tonsillectomy are at least three to
seven episodes of tonsillitis per year in spite of medical therapy, but
there is no international consensus.14
In Ayurvedic thought, tonsillitis can be correlated to Tundikeri,
which is one of the Urdhvajatrugata Roga (diseases of the head and
neck); it is mentioned in Talugata Roga15 (diseases of the palate) as
well as Kanthagata Roga (diseases of the throat).16 Ayurveda ex-
plains that it is caused by the vitiation and imbalance of Doshasrsity. Production and hosting by Elsevier Taiwan LLC. All rights reserved.
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Kapha and Rakta (blood) is preceded by impaired digestive capacity
(Mandagni/Vishamagni) and obstruction of channels (Sroto Avar-
odha) namely Annavaha Srotas (gastrointestinal tract) and Prana-
vaha Srotas (respiratory tract) which is manifested as difﬁculty in
swallowing, mouth breathing, choking spells at night, etc.15,16 The
present study was conducted to explore the efﬁcacy of Kumar-
abharana Rasa (KR) in the management of chronic tonsillitis in
children. KR has a combined action over vitiated Doshas due to its
anti-inﬂammatory, antimicrobial, immunomodulatory, and rejuvi-
native effects.
2. Materials and methods
2.1. Design
This study was an open-labeled double-arm setting with a pre-
and post-test design.
2.2. Participants
Children presenting with any of the symptoms of chronic
tonsillitis (Tundikeri), i.e., Kathina Shotha (enlargement of tonsils),
Ragatwa (hyperemia), Galoparodha (dysphagia), Mukha Daur-
gandhya (halitosis), Lasikagranthi Vriddhi (enlargement of lymph
nodes), and Jwara (fever) were selected and registered from Kau-
marabhritya (Ayurvedic Pediatrics) outpatient department of SDM
College of Ayurveda and Hospital, Hassan between June 2012 and
December 2013. Before initiating the study ethical clearance was
obtained from institutional ethics committee of SDM College of
Ayurveda and Hospital, Hassan (IEC No. SDMAH/IEC/57/11-12
dated 01-04-2012). Written informed consent was taken from
the parents of the study participants before any study-related
procedures were performed. Inclusion criteria were: children of
both sexes between 5 and 10 years of age and who had repeated
attacks of tonsillitis (chronic infections) in the past year. Exclusion
criteria were: patients with acute tonsillitis, peritonsillar abscess,
tonsillar cyst, tonsillolith, or any other systemic disorders; patients
who had taken systemic steroids and/or antibiotics in the past 4
weeks.
2.3. Study drugs
2.3.1. Kumarabharana Rasa
This is a compound drug comprising Bhasmas (puriﬁed calx) of
Swarna (gold), Rajata (silver), Pravala (coral) and Churna (powder)
of Yastimadhu (Glycyrrhiza glabra Linn.), Amlaki (Emblica ofﬁcinalis
Gaertn.), Ashwagandha (Withania somnifera Dunal.), Sunthi (Zin-
giber ofﬁcinale Rosc.), Pippali (Piper longum Linn.), Haritaki (Termi-
nalia chebula Retz.), Vacha (Acorus calamus Linn.). All these drugs
were processed with Swarasa (extract juice) of Guduchi (Tinospora
cordifolia Miers ex Hook. F. & Thoms), Brahmi (Centella asiatica
Linn.), and Tulsi (Ocimum tenuiﬂorum Linn.) separately then pre-
pared in tablet form.17
2.3.2. Godhuma Vati (placebo)
Wheat powder was processed and prepared in tablet form.
Raw drugs were obtained from SDM Pharmacy, Udupi and
authenticated in the Department of Dravyaguna, SDM College of
Ayurveda and Hospital, Hassan. The medicine was prepared in
the Teaching Pharmacy, SDM College of Ayurveda and Hospital,
Hassan. Tablets of 500 mg were prepared and preserved in air-
tight, properly labeled plastic bottles containing 30 tablets in
each.2.4. Intervention
A total of 53 patients were screened for chronic tonsillitis.
Among them 40 patients were enrolled into the study fulﬁlling the
inclusion and exclusion criteria. A convenient sampling technique
was adopted, with 20 patients each in study group (KR) and the
control group (Godhuma Vati). The patients in the study groupwere
treated with KR (tablet form) at a dose of 500 mg once daily for 30
days. The patients in the control group were treated with Godhuma
Vati (tablet form) at a dose of 500mg once daily for 30 days. Parents
were advised to crush the tablet to a powder and to give it to the
child using honey as Anupana (vehicle for drug administration)
before food, in the morning, for both groups.
2.5. Observation-based assessment criteria
2.5.1. Subjective parameters
The assessment of the signs and symptoms were done on the
Day 0 and Day 31. Severity was assessed by grading 1e5 (absence to
severe) for each symptom. Kathina Shotha (enlargement of tonsils)
e no enlargement, enlarged within anterior pillars, enlargedwithin
posterior pillars, enlarged beyond pillars, kissing tonsils with sleep
apnea. Ragatwa (hyperemia) e no hyperemia, hyperemia of tonsil
surface, pinkish appearance of pillars, reddish appearance of sur-
roundings, reddish appearance of surroundings and pharynx.
Galoparodha (dysphagia) e no pain while swallowing, pain during
swallowing solid food substances, pain during swallowing semi-
solid food substances, pain during swallowing liquid food sub-
stances, continuous pain/unable to swallow. Mukha Daurgandhya
(halitosis) e no halitosis, foul breath experienced by the patient
only, foul breath experienced by the patient and friends/parents,
foul breath is experienced by a group of surrounding people, foul
breath is experienced as soon as the patient opens the mouth.
Lasikagranthi Vriddhi (enlargement of lymph nodes) e no palpable
lymph nodes, palpable lymph nodes unilateral/warm, palpable
lymph nodes bilateral/soft/ﬂuctuant, palpable lymph nodes bilat-
eral which are hard, palpable lymph nodes bilateral with tender-
ness. Jwara (fever) was measured according in degrees Fahrenheit
(normal was 98.6 Fahrenheit).
2.5.2. Objective parameters
Assessments were based on routine laboratory blood in-
vestigations e hemoglobin % (Hb%), total leukocyte count (TLC),
neutrophils, lymphocytes, eosinophils, and erythrocyte sedimen-
tation rate (ESR) were performed on Day 0 and Day 31.
2.6. Statistical analysis
For the statistical analysis, the Statistical Package for Social
Sciences (SPSS) version 16 (SSPS Inc., Chicago. IL, USA) was used.
The independent samples t test and Mann-Whitney U test (for
between-subjects designs) and paired samples t test and the Wil-
coxon test (for within-subjects designs) were done.
3. Results
In present study 40 patients were registered, of which only 37
participants completed the study. The sociodemographic proﬁle of
the participants shows that 57.5% (23) weremale and the rest 42.5%
(17) were females. The age groups of 5e6, 7e8, and 9e10 years
consisted of 18 (45%), 27.5% (11), 27.5% (11) participants, respec-
tively. The majority (90%, 36) of the participants belonged to the
Hindu religion. Socioeconomic assessment revealed that 37.5%
belonged to the lower-middle class followed by 30% in the upper-
middle class strata. Prakriti (genetic phenotype) yielded the
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was consumed by 80% (32) of the participants. Sleep patterns
showed the 60% (24 participants) slept for around 10 hours/day but
62.5% (25) had disturbed sleep, while 37.5% (15) had normal sleep.
The family history of the participants highlighted that 25% (10) had
a positive family history of chronic tonsillitis. Duration of tonsillitis
revealed that 27.5% (11) participants had a duration of tonsillitis for
a period of 3 years or more, 17.5% (7) had a duration of tonsillitis for
a period of 2 years or more and 55% (22) had a duration of onset of
tonsillitis for a period of 1 year or less. Poor oral hygiene was
observed among 67.5% (27) participants and only 10% (4) had good
oral hygiene.
Chief complaints reported were throat pain among 10% (4) pa-
tients, difﬁculty in deglutition in 17.5% (7) patients, halitosis in
12.5% (5) patients, fever in 10% (4) patients, breathing difﬁculty
among 20% (8) patients (16.66%) with complaints of mouth
breathing in 22.5% (9) patients. Only 5% (2) reported having Jugulo-
digastric lymphadenopathy and 2.5% (1) having enlarged tonsils.
Clinical diagnosis revealed 62.5% (25) patients with chronic
parenchymatous tonsillitis, 32.5% (13) patients with chronic
follicular tonsillitis and only 5% (2) were diagnosed as chronic
ﬁbroid tonsillitis. Within the group (Wilcoxon signed ranks test)
statistical signiﬁcance (p < 0.05) on signs and symptoms of chronic
tonsillitis was found for KR intervention, but nothing signiﬁcant
was observed with Godhuma Vati intervention (Table 1). However,
between groups (Mann Whitney U test), the effects of KR on signs
and symptoms of chronic tonsillitis was found to be signiﬁcant
(p< 0.05; Table 2). Routine laboratory blood investigations assessed
within the KR (study group) showed statistical signiﬁcance
(p < 0.05) on Hb%, TLC, lymphocytes and ESR, whereas Godhuma
Vati (placebo) were nonsigniﬁcant (Table 3). The comparisons on
the effect of KR (study group) and Godhuma Vati (placebo group) on
laboratory investigations and fever were nonsigniﬁcant (p > 0.05)
as detailed in Table 4.4. Discussion
CHT is an inﬂammation of the tonsils caused by a microbial
infection. The symptoms are usually mild and often related to the
common cold. In streptococcal infection the tonsils often swell and
become coated and the throat is sore. The patient has a tempera-
ture, foul-smelling breath and may feel quite ill. Therefore drugs
with anti-inﬂammatory and immunomodulatory effects may be
useful for treatment of CHT. Ayurveda, as well as recent experi-
mental results indicate the ingredients of a poly-herbo-mineral
formulation KR as having anti-inﬂammatory, antimicrobial, and
immunomodulatory effects. It is substantiated by the clinical ob-
servations among tonsillitis patients. The key ingredients being the
metallic Bhasmas (puriﬁed calx), like Swarna Bhasma, is prepared
by incinerating gold processed with herbal preparations.18,19
Swarna Bhasma promotes immunity through phagocytosis.20 GoldTable 1
Effect of Kumarabharana Rasa and Godhuma Vati on signs and symptoms of chronic
tonsillitis (BT & AT) e test statistics within the groups (Wilcoxon signed ranks test).
Sign and symptoms Kumarabharana Rasa Godhuma Vati
Z P (2-tailed) Z P (2-tailed)
Kathina Shotha
(enlargement of tonsils)
3.100 0.002 1.414 0.157
Ragatwa (hyperemia) 3.256 0.001 1.890 0.059
Galoparodha (dysphagia) 3.580 0.000 0.378 0.705
Mukha Daurgandhya (halitosis) 3.341 0.001 0.000 1.000
Lasikagranthi Vriddhi
(enlargement of lymph nodes)
3.473 0.001 1.633 0.102poly-herbal formulations are found to increases vitality and im-
munity.21 The clinical applications of Swarna Bhasma and gold salts
in Ayurveda are known for rejuvenation and immunomodulation
for some chronic diseases.22 Gold nanoparticles have signiﬁcant
applications in targeted drug delivery.23,24 Swarna Bhasma contains
gold particles in the size range of nanoparticles.25 Recent studies
shows that Swarna Bhasma contained not only gold, but also several
microelements (Fe, Al, Cu, Zn, Co, Mg, Ca, As, Pb, etc.). Animal model
studies show Swarna Bhasma-treated animals signiﬁcantly
increased superoxide dismutase and catalase activity, which are
responsible for reducing free radical concentrations in the body.19
The antioxidant effect of Swarna Bhasma is considered to be one
of the mechanisms for the immunomodulatory mode of action of
the formulation. Rajata Bhasma (silver calx) is a nanoparticulate
complex of silver along with Sn, Cd, Mg, K, Na, S, Ca, P, Si, Al, Cl, Ar,
In, Fe, Cu, Ba, Hg, or Cr.26 Recent scientiﬁc trends indicate emer-
gence of metallic silver in the form of silver nanoparticles as a
potential antimicrobial agent, specially important, as several
pathogenic bacteria have developed resistance against various
antibiotics.27
Herbal components like Amalaki (Phylanthus embellica)28,29 and
Guduchi (Tinospora cordifolia)30 are having nourishing and rejuvi-
native property. Experimental studies reveal their immunostimu-
lant activity which combats sepsis in animals.31e36 Vacha, Sunthi,
Pippali, Ashwagandha, Yastimadhu, Amalaki, and Haritaki all have
immunomodulatory properties.37-40 Pippali is an important drug
for the treatment of cough, common cold, and is useful as a
digestive. The active principle piperine is known for its bio-
enhancing and anti-inﬂammatory effects.41 Yasthimadhu is a
prominent Rasayana known for its immunomodulatory, anti-
inﬂammatory, anti-allergic and antiviral activities. It also en-
hances permeability in drug delivery systems.42 Yastimadhu
(Glycerrhiza glabra) also has cytoprotective and demulcent effects
and is a popular home remedy for minor throat infections. Bio-
logically active substances in liquorice root include glycyrrhizic acid
(GL) and its aglycone (GA), phenolic compounds, oligosaccharides
and polysaccharides, lipids, sterine, etc. Many researchers have
suggested that the effects on the production of interferon (IFN) and
Th2 cytokinesmight be one of themechanisms involved in the anti-
infective process. Recently, glycyrrhizin has been found to be active
in inhibiting replication of the severe acute respiratory syndrome
(SARS)-associated virus (FFM-1 and FFM-2) and also H5N1 inﬂu-
enza A virus-infected cells. GL is also reported to have modulatory
effects on the complement system. Reports indicate that GL blocks
C5 or a more distal stage of the complement cascade, suggesting
that it might have a role in preventing tissue injury not only in
chronic hepatitis, but also in autoimmune and inﬂammatory dis-
eases. Chemical modiﬁcation of GL and GA has been tried, and a
signiﬁcant improvement in anti-inﬂammatory, antiallergic, and
antiulcer activities was observed. These observations indicate
immune-modulating and biological response modiﬁer activities
associated with GL. Tinospora cordifolia (TC) is known for its
immunomodulatory and cytoprotective activities Quaternary al-
kaloids and biotherapeutic diterpene glucosides of TC (syringin,
cordiol, cordioside, and coriofolioside) showed an immunopoten-
tiating activity. Research work has been conducted on berberine,
jatrorrhizine, tinosporaside, and columbin, which shows a possible
mechanism of immunomodulatory activity as an activation of
macrophages, leading to increases in granulocyteemacrophage
colony-stimulating factor (GM-CSF), leukocytosis, and improved
neutrophil function. TC also inhibits C3 convertase of the classical
complement pathway. Research on polysaccharide (a-D-glucan)
derived from TC shows the activation of nuclear killer (NK) cells,
complement system, and Th1 pathway cytokines, coupled with low
nitric oxide synthesis.43 Aswagandha has shown promising
Table 2
Comparison on the effect of Kumarabharana Rasa (study group) and Godhuma Vati (placebo group) on signs and symptoms e test statisticsb between the groups (Mann
Whitney U test).
BT & AT Kathina Shotha
(enlargement of tonsils)
Ragatwa
(hyperemia)
Galoparodha
(dysphagia)
Mukha Daurgandhya
(halitosis)
Lasikagranthi
Vriddhi (enlargement
of lymph nodes)
Mann-Whitney U 60.000 101.500 50.000 54.000 65.500
Wilcoxon W 213.000 254.500 203.000 207.000 218.500
Z 3.856 2.335 3.910 3.932 3.465
Asymp. Sig. (2-tailed) 0.000 0.020 0.000 0.000 0.001
Exact Sig. [2*(1-tailed Sig.)] 0.001a 0.036a 0.000a 0.000a 0.001a
a Not corrected for ties.
b Grouping variable: group.
Table 3
Effect of Kumarabharana Rasa and Godhuma Vati on laboratory investigations and fever in chronic tonsillitis (BT & AT) e paired samples test (within group).
Parameters Kumarabharana Rasa Godhuma Vati
Mean difference Std. deviation Std. error mean p Mean difference Std. deviation Std. error mean p
Hb% 0.34000 0.69008 0.15431 0.040 0.16471 .86092 .20880 0.442
TLC 1.83700 3174.19878 709.77242 0.018 5.35294 2708.9991 657.02881 0.427
Neutrophils 4.00000 9.48683 2.12132 0.075 0.58824 7.53375 1.82720 0.752
Lymphocytes 4.30000 8.54770 1.91132 0.037 3.35294 7.38191 1.79038 0.079
Eosinophils 0.40000 1.14248 0.25547 0.134 0.70588 1.53153 0.37145 0.076
ESR 1.08000 16.80413 3.75752 0.010 1.64706 10.32558 2.50432 0.520
Temperature 0.39500 0.87327 0.19527 0.057 0.08235 2.47897 0.60124 0.893
Table 4
Comparison on the effect of Kumarabharana Rasa (study group) and Godhuma Vati
(placebo group) on laboratory investigations and fever e independent samples test
(between groups).
Differences BT & AT t Sig. 2-tailed (p) Mean diff. Std. error diff.
Hb% 0.688 0.496 0.17529 0.25496
TLC 1.328 0.193 1301.70588 979.95025
Neutrophils 1.560 0.128 4.31176 2.76446
Lymphocytes 0.357 0.723 0.94706 2.65088
Eosinophils 0.695 0.492 0.30588 0.44022
ESR 1.952 0.059 9.15294 4.68889
Temperature 0.778 0.442 0.46088 0.59237
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Sunthi (Zingiber ofﬁcinalis) has anti-inﬂammatory property which
inhibits LPS-induced NF-kB activation by preventing degradation of
the IkB-a, as well as the phosphorylation of ERK1/2, SAPK/JNK, and
p38 MAPKs which were associated with a decrease in the expres-
sion of inducible nitric oxide synthase (iNOS) and cyclooxyenase-2
(COX-2).45 Vacha (Acorus calamus) is reported for its inhibitory ef-
fect on mast cell-dependent anaphylactic reactions in allergic re-
actions of the respiratory tract.46 Amla (Phyllanthus emblica) has
been reported to suppress the expression of LPS-induced pro-in-
ﬂammatory genes (COX-2, iNOS, TNF-a, IL-16, and IL-6) in RAW
264.7 murine macrophage cells in a dose-dependent manner.47
Honey is known to enhance the action of these medicines, and
has a potential immunomodulatory effect.48e515. Conclusion
Thus the poly-herbo-mineral formulation KR has a combined
mechanism of action on tonsillitis by reducing the number of at-
tacks. From the Ayurvedic perspective it controls the imbalance of
Doshas and thus effectively reduces the signs and symptoms of
chronic tonsillitis. However, following the reverse pharmacological
perspective we ﬁnd scientiﬁc evidence of its components against
inﬂammation and microbial invasion via multiple mechanisms
mostly as immunomodulators, as discussed above. Future studieson KR formulation along the lines of reverse pharmacology may
produce more conclusive information about its combined mecha-
nism of action at the molecular level.
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